Liquidia Corporation

Executive Summary

Liquidia Corporation is a late-stage biopharmaceutical company focused on developing and commercializing inhaled therapies for pulmonary diseases using its proprietary PRINT® particle engineering technology. Its lead product, YUTREPIA™ (treprostinil) inhalation powder, received FDA approval in November 2024 for the treatment of pulmonary arterial hypertension (PAH) in NYHA Functional Class II-III patients. However, commercial launch has been delayed due to ongoing patent litigation with United Therapeutics, which holds patents on treprostinil-based therapies. The company's PRINT® platform enables precise particle design, potentially offering improved lung deposition and ease of use over existing inhaled treprostinil products. Liquidia also has a pipeline candidate, LIQ861, which is a next-generation dry powder formulation of treprostinil. The company's valuation reflects the high unmet need in PAH and the potential for YUTREPIA to capture market share if litigation is resolved favorably. Key risks include the uncertain outcome of patent disputes and competition from approved therapies like Tyvaso DPI.

Upcoming Catalysts (preview)

• Q4 2026Resolution of patent litigation allowing YUTREPIA launch55% success
• Q2 2027FDA decision on LIQ861 NDA (potential label expansion for YUTREPIA)40% success
• TBDPartnership or licensing deal for ex-US commercialization of YUTREPIA30% success